Status:
TERMINATED
Study To Assess The Safety And Tolerability Of Increasing Single Doses Of ATR-107 (PF-05230900) In Healthy People
Lead Sponsor:
Pfizer
Conditions:
Healthy
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
This is a "first in human" study to determine the safety and tolerability of the drug after single doses. Nine doses of increasing strength will be injected or infused (given into a vein) to 9 differe...
Detailed Description
First in human single dose study. Study terminated 12 October 2011. The ATR-107 Development team reached a recommendation to terminate further development of ATR-107 (PF-05230900). This was based on a...
Eligibility Criteria
Inclusion
- Females of non-childbearing potential
- Body mass index between 17.5 to 30.5 and body weight \> 50 kg
Exclusion
- History of significant medical illness
- Positive urine drug screen or alcohol dependance
- Smoking \> 10 cigarettes per day
Key Trial Info
Start Date :
June 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT01162889
Start Date
June 1 2010
End Date
January 1 2012
Last Update
March 15 2012
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
New Haven, Connecticut, United States, 06511
2
Pfizer Investigational Site
Overland Park, Kansas, United States, 66211